24/7 Market News Snapshot 29 May, 2025 – Genprex, Inc. Common Stock (NASDAQ:GNPX)

May 29, 2025

DENVER, Colo., 29 May, 2025 (www.247marketnews.com) – (NASDAQ:GNPX) are discussed in this article.
Genprex, Inc. (GNPX) has demonstrated significant market momentum, opening at $0.28 and soaring to $0.334, reflecting an impressive gain of approximately 19.24% in recent trading. This surge follows a previous close of $0.280, indicating robust investor interest and heightened market activity with a current trading volume of 5.47 million shares. Continued trading above the prior close may attract additional buyers, further strengthening the upward trajectory of this low-priced stock.

In parallel, Genprex proudly announces its selection to present at the prestigious 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, set for May 30 to June 3. This invitation underscores the company’s commitment to pioneering innovative therapies for cancer patients. Genprex’s presentation will focus on the Acclaim-3 Phase 1/2 clinical trial, which seeks to assess the efficacy of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq® for the treatment of Extensive Stage Small Cell Lung Cancer (ES-SCLC).

The trial aspires to overcome the limitations of existing treatments, particularly the current median progression-free survival rate of just 2.6 months among patients on Tecentriq maintenance therapy. Ryan Confer, Genprex’s President and CEO, emphasized the company’s dedication to enhancing patient outcomes, stating that reintroducing the TUSC2 gene aims to significantly improve survival rates. Preliminary studies suggest the combination therapy could notably enhance cancer treatment efficacy.

Details on trial objectives, participant criteria, dosing schedules, and assessment metrics will be included in the presentation at ASCO. This event marks a critical step in Genprex’s mission to transform cancer care, and all presentation materials will later be accessible on the company’s website, further promoting knowledge sharing within the oncology community.

Related news for (GNPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.